Neola Medical AB (NEOLA) - Net Assets
Based on the latest financial reports, Neola Medical AB (NEOLA) has net assets worth Skr78.46 Million SEK (≈ $8.44 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr82.61 Million ≈ $8.89 Million USD) and total liabilities (Skr4.15 Million ≈ $446.82K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read NEOLA total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr78.46 Million |
| % of Total Assets | 94.97% |
| Annual Growth Rate | 31.51% |
| 5-Year Change | 192.87% |
| 10-Year Change | N/A |
| Growth Volatility | 49.88 |
Neola Medical AB - Net Assets Trend (2018–2024)
This chart illustrates how Neola Medical AB's net assets have evolved over time, based on quarterly financial data. Also explore NEOLA total assets for the complete picture of this company's asset base.
Annual Net Assets for Neola Medical AB (2018–2024)
The table below shows the annual net assets of Neola Medical AB from 2018 to 2024. For live valuation and market cap data, see Neola Medical AB (NEOLA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr68.96 Million ≈ $7.42 Million |
-12.74% |
| 2023-12-31 | Skr79.03 Million ≈ $8.50 Million |
+17.10% |
| 2022-12-31 | Skr67.48 Million ≈ $7.26 Million |
+66.08% |
| 2021-12-31 | Skr40.63 Million ≈ $4.37 Million |
+72.57% |
| 2020-12-31 | Skr23.55 Million ≈ $2.53 Million |
+119.59% |
| 2019-12-31 | Skr10.72 Million ≈ $1.15 Million |
-19.55% |
| 2018-12-31 | Skr13.33 Million ≈ $1.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neola Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1099.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.01 Million | 7.27% |
| Other Comprehensive Income | Skr45.40 Million | 65.83% |
| Other Components | Skr99.08 Million | 143.67% |
| Total Equity | Skr68.96 Million | 100.00% |
Neola Medical AB Competitors by Market Cap
The table below lists competitors of Neola Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Burford Capital Limited
LSE:BUR
|
$10.07 Million |
|
Bawat Water Technologies AB
ST:BAWAT
|
$10.07 Million |
|
Memphasys Ltd
AU:MEM
|
$10.07 Million |
|
BOA Resources Ltd
AU:BOA
|
$10.08 Million |
|
Impax Environmental Markets PLC
LSE:IEM
|
$10.07 Million |
|
UET United Electronic Technology AG
XETRA:CFC
|
$10.06 Million |
|
InCoax Networks AB
ST:INCOAX
|
$10.06 Million |
|
Digjam Limited
NSE:DIGJAMLMTD
|
$10.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neola Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 79,028,000 to 68,963,000, a change of -10,065,000 (-12.7%).
- Net loss of 10,064,000 reduced equity.
- New share issuances of 20,000,000 increased equity.
- Other comprehensive income decreased equity by 10,057,000.
- Other factors decreased equity by 9,944,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-10.06 Million | -14.59% |
| Share Issuances | Skr20.00 Million | +29.0% |
| Other Comprehensive Income | Skr-10.06 Million | -14.58% |
| Other Changes | Skr-9.94 Million | -14.42% |
| Total Change | Skr- | -12.74% |
Book Value vs Market Value Analysis
This analysis compares Neola Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.58x to 1.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr0.76 | Skr1.20 | x |
| 2019-12-31 | Skr0.61 | Skr1.20 | x |
| 2020-12-31 | Skr2.47 | Skr1.20 | x |
| 2021-12-31 | Skr2.23 | Skr1.20 | x |
| 2022-12-31 | Skr2.59 | Skr1.20 | x |
| 2023-12-31 | Skr1.42 | Skr1.20 | x |
| 2024-12-31 | Skr0.98 | Skr1.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neola Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-14.59%) is above the historical average (-16.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -5.71% | -132.35% | 0.04x | 1.05x | Skr-2.09 Million |
| 2019 | -24.30% | -16287.50% | 0.00x | 1.14x | Skr-3.68 Million |
| 2020 | -28.53% | -21667.74% | 0.00x | 1.10x | Skr-9.07 Million |
| 2021 | -16.37% | -1064.48% | 0.01x | 1.08x | Skr-10.72 Million |
| 2022 | -15.34% | 0.00% | 0.00x | 1.12x | Skr-17.10 Million |
| 2023 | -11.40% | 0.00% | 0.00x | 1.09x | Skr-16.91 Million |
| 2024 | -14.59% | 0.00% | 0.00x | 1.07x | Skr-16.96 Million |
Industry Comparison
This section compares Neola Medical AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neola Medical AB (NEOLA) | Skr78.46 Million | -5.71% | 0.05x | $10.07 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume chan… Read more